# Regeneron Pharmaceuticals Moat

Status: published. Policy: company-analysis-1.

Regeneron has a narrow intangible-asset moat supported by approved medicines, demonstrated commercial demand and continued regulatory achievements. EYLEA HD's approved extended dosing and growth in Dupixent and Libtayo support current differentiation. Unspecified patent duration, competitive alternatives, manufacturing setbacks and constrained pricing freedom prevent a wide-moat conclusion. Realized net pricing power remains unestablished.

## intangible_assets

Approved therapies, protected intellectual property and demonstrated development execution support commercially valuable product differentiation. EYLEA HD's FDA-approved dosing intervals of up to 20 weeks are a current achievement; Dupixent and Libtayo sales growth demonstrates demand. These disclosures do not establish comparative superiority or a separate moat for investigational programs.

Durability: Multiple approved products and additional indications support continued differentiation, but the passages do not establish remaining product-specific patent or exclusivity periods. Continued innovation can replenish the portfolio but cannot guarantee durable protection.

Risks: Branded and biosimilar competition, alternative mechanisms, reimbursement restrictions and discounts can erode commercial value. Third-party manufacturing inspection findings have already delayed regulatory applications. Revenue remains concentrated in EYLEA HD, EYLEA and Dupixent.

Invalidation: The narrow-moat thesis would fail if competing therapies or biosimilars caused sustained demand and net-sales erosion across the principal franchises without replacement from approved products, or if loss of protection, reimbursement access or reliable supply materially eliminated their differentiated commercial value.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm](https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm) · 2026-02-04
- [https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm](https://www.sec.gov/Archives/edgar/data/872589/000087258926000025/regn-20260630.htm) · 2026-07-30
- [https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm](https://www.sec.gov/Archives/edgar/data/872589/000130817926000340/regn-20260424.htm) · 2026-04-24
- [https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm](https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm) · 2025-02-05
- [https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm](https://www.sec.gov/Archives/edgar/data/872589/000180422024000009/regn-20231231.htm) · 2024-02-05
- [https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm](https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm) · 2026-04-29

[JSON](https://beanvest.com/stock/regn/moat.json)